Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders


Author index

Page Path
HOME > Browse Articles > Author index
Taku Hatano 4 Articles
α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders
Taku Hatano, Ayami Okuzumi, Gen Matsumoto, Taiji Tsunemi, Nobutaka Hattori
J Mov Disord. 2024;17(2):127-137.   Published online April 9, 2024
  • 1,952 View
  • 266 Download
AbstractAbstract PDF
Mutations in the SNCA gene, which encodes α-synuclein (α-syn), play a key role in the development of genetic Parkinson’s disease (PD). α-Syn is a major component of Lewy bodies in PD and glial cytoplasmic inclusions in multiple system atrophy (MSA). Rapid eye movement sleep behavior disorder patients often progress to PD, dementia with Lewy bodies, or MSA, which are collectively known as α-synucleinopathies. The loss of dopaminergic neurons with Lewy bodies precedes motor dysfunction in these diseases, but the mechanisms of neurodegeneration due to α-syn aggregation are poorly understood. Monitoring α-syn aggregation in vivo could serve as a diagnostic biomarker and help elucidate pathogenesis, necessitating a simple and accurate detection method. Seed amplification assays (SAAs), such as real-time quaking-induced conversion and protein misfolding cyclic amplification, are used to detect small amounts of abnormally structured α-syn protofibrils, which are central to aggregation. These methods are promising for the early diagnosis of α-synucleinopathy. Differences in α-syn filament structures between α-synucleinopathies, as observed through transmission electron microscopy and cryo-electron microscopy, suggest their role in the pathogenesis of neurodegeneration. SAAs may differentiate between subtypes of α-synucleinopathy and other diseases. Efforts are also being made to identify α-syn from blood using various methods. This review introduces body fluid α-syn biomarkers based on pathogenic α-syn seeds, which are expected to redefine α-synucleinopathy diagnosis and staging, improving clinical research accuracy and facilitating biomarker development.
Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
Noriko Nishikawa, Taku Hatano, Daiki Kamiyama, Haruna Haginiwa-Hasegawa, Genko Oyama, Nobutaka Hattori
J Mov Disord. 2022;15(3):290-292.   Published online July 26, 2022
  • 1,636 View
  • 128 Download
PDFSupplementary Material
Current Status of Telemedicine for Parkinson’s Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey
Mayuko Ogawa, Genko Oyama, Satoko Sekimoto, Taku Hatano, Nobutaka Hattori
J Mov Disord. 2022;15(1):58-61.   Published online December 24, 2021
  • 4,863 View
  • 237 Download
  • 6 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary Material
Using telemedicine is a way to improve the accessibility of specialists for patients with Parkinson’s disease (PD); however, it is not widely used in Japan. We investigated the efficacy of telemedicine in PD by using a single-center cross-sectional questionnaire survey.
We sent a questionnaire to patients who agreed to participate from among 52 patients with PD who had used telemedicine services at Juntendo University Hospital from October 2017 to November 2018. Caregivers were asked to respond to one question separately.
A total of 38 patients responded to the questionnaire. Most patients were satisfied with the telemedicine consultation (7.8 ± 1.9), reporting that it was effective in reducing their travel burden. Twenty-one patients attended a telemedicine consultation with their caregivers, and their satisfaction was high (8.4 ± 1.8).
In a specific cohort in Japan, patients with PD and their caregivers were mostly satisfied with the telemedicine service.


Citations to this article as recorded by  
  • A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease
    Jae Young Joo, Ji Young Yun, Young Eun Kim, Yu Jin Jung, Ryul Kim, Hui-Jun Yang, Woong-Woo Lee, Aryun Kim, Han-Joon Kim
    Journal of Movement Disorders.2024; 17(1): 89.     CrossRef
  • Expert teleconsultation involving patients and their primary neurologists for the management of multiple sclerosis in regions without specialists
    Yusei Miyazaki, Shigehisa Ura, Kazuhiro Horiuchi, Takeshi Matsuoka, Hideki Houzen, Kazufumi Tsuzaka, Yuichi Makino, Manami Koshida, Genko Oyama, Chika Sato, Ryoji Naganuma, Itaru Amino, Sachiko Akimoto, Masaaki Niino, Naoya Minami, Eri Takahashi, Susumu O
    Clinical and Experimental Neuroimmunology.2024;[Epub]     CrossRef
  • Effects of LSVT-BIG via telerehabilitation on non-motor and motor symptoms and quality of life in Parkinson’s disease
    Yasemin Ekmekyapar Fırat, Türkan Turgay, Selver Seval Soğan, Pınar Günel Karadeniz
    Acta Neurologica Belgica.2023; 123(1): 207.     CrossRef
  • A Narrative Review of Current Status and Future Perspective of Telemedicine for Parkinson's Disease, Dementia, and Intractable Neurological Diseases in Japan
    Juntendo Medical Journal.2023; 69(1): 14.     CrossRef
  • A multicenter, prospective, observational study to assess the satisfaction of an integrated digital platform of online medical care and remote patient monitoring in Parkinson's disease
    Makoto Shiraishi, Tsutomu Kamo, Ryuya Kumazawa, Naoshi Sasaki, Kenji Isahaya, Hisanao Akiyama, Yoshihiko Furusawa, Reiko Onodera, Jovelle Fernandez, Masaru Otsuka, Yoshihisa Yamano
    Neurology and Clinical Neuroscience.2023; 11(3): 152.     CrossRef
  • New era of artificial intelligence and machine learning-based detection, diagnosis, and therapeutics in Parkinson’s disease
    Rohan Gupta, Smita Kumari, Anusha Senapati, Rashmi K. Ambasta, Pravir Kumar
    Ageing Research Reviews.2023; 90: 102013.     CrossRef
  • Feasibility study of Internet video-based speech-language activity for outpatients with primary progressive aphasia
    Shinji Higashi, Yuko Koshibe, Takehiro Miyazaki, Ryohei Watanabe, Hanako Nakanome, Takeshi Inoue, Takashi Asada, Tetsuaki Arai, Kenjiro Ono
    PLOS ONE.2023; 18(7): e0288468.     CrossRef
  • Feasibility and efficacy of video-call speech therapy in patients with Parkinson's disease: A preliminary study
    Hee Jin Chang, Jiae Kim, Jae Young Joo, Han-Joon Kim
    Parkinsonism & Related Disorders.2023; 114: 105772.     CrossRef
  • Perspectives on Telemedicine
    彦光 大山, 信孝 服部
    Iryou kikigaku (The Japanese journal of medical instrumentation).2022; 92(3): 331.     CrossRef
Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
Juan Miguel Pilar Bautista, Genko Oyama, Maierdanjiang Nuermaimaiti, Satoko Sekimoto, Fuyuko Sasaki, Taku Hatano, Kenya Nishioka, Masanobu Ito, Atsushi Umemura, Yuji Ishibashi, Yasushi Shimo, Nobutaka Hattori
J Mov Disord. 2020;13(1):57-61.   Published online January 31, 2020
  • 6,099 View
  • 154 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDF
The long-term efficacy of deep brain stimulation (DBS) for motor fluctuations in advanced Parkinson’s disease (PD) has been well established; however, motor fluctuations may recur over time despite multiple adjustments of DBS settings and medications.
We conducted a retrospective chart review of three patients for whom levodopa-carbidopa intestinal gel (LCIG) was additionally administered as a rescue therapy for secondary DBS failure due to the recurrence of motor fluctuations.
The three patients had advanced PD with a disease duration of 14–19 years, and had undergone DBS for motor fluctuations refractory to standard medical management. LCIG was administered to the patients because of symptom recurrence years after DBS and provided complementary effects in all patients.
The cases presented here show that rescue LCIG therapy may be a complementary treatment option for patients with post-DBS advanced PD who have a recurrence of troublesome motor complications.


Citations to this article as recorded by  
  • Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease
    Dominik Pürner, Mohammad Hormozi, Daniel Weiß, Michael T. Barbe, Hannah Jergas, Tino Prell, Eileen Gülke, Monika Pötter-Nerger, Björn Falkenburger, Lisa Klingelhöfer, Pia K. Gutsmiedl, Bernhard Haslinger, Angela M. Jochim, Andreas Wolff, Nils Schröter, Mi
    Neurology.2023;[Epub]     CrossRef
  • Combining Device‐Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review
    Iro Boura, Nikolaos Haliasos, Ιrene‐Areti Giannopoulou, Dimitrios Karabetsos, Cleanthe Spanaki
    Movement Disorders Clinical Practice.2021; 8(5): 750.     CrossRef
  • Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
    Daniël van Poppelen, Annelie N.M. Tromp, Rob M.A. de Bie, Joke M. Dijk
    Journal of Personalized Medicine.2021; 11(6): 547.     CrossRef
  • Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
    Valentina Leta, Haidar S. Dafsari, Anna Sauerbier, Vinod Metta, Nataliya Titova, Lars Timmermann, Keyoumars Ashkan, Michael Samuel, Eero Pekkonen, Per Odin, Angelo Antonini, Pablo Martinez-Martin, Miriam Parry, Daniel J. van Wamelen, K. Ray Chaudhuri
    Journal of Personalized Medicine.2021; 11(8): 773.     CrossRef
  • Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
    Yassine Noui, Monty Adam Silverdale, Julian Evans, Lucy Partington-Smith, Christopher Kobylecki
    Journal of Movement Disorders.2021; 14(3): 239.     CrossRef
  • The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
    Joke M. Dijk, Alberto J. Espay, Regina Katzenschlager, Rob M.A. de Bie, Bastiaan R. Bloem, Patrik Brundin
    Journal of Parkinson's Disease.2020; 10(s1): S65.     CrossRef

JMD : Journal of Movement Disorders Twitter